UY26218A1 - COMBINATION OF MTP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THEIR USE IN MEDICINES. LAW 17,164.- - Google Patents
COMBINATION OF MTP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THEIR USE IN MEDICINES. LAW 17,164.-Info
- Publication number
- UY26218A1 UY26218A1 UY26218A UY26218A UY26218A1 UY 26218 A1 UY26218 A1 UY 26218A1 UY 26218 A UY26218 A UY 26218A UY 26218 A UY26218 A UY 26218A UY 26218 A1 UY26218 A1 UY 26218A1
- Authority
- UY
- Uruguay
- Prior art keywords
- combination
- inhibitors
- hmg
- coa reductase
- medicines
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Abstract
La invención se refiere al uso de una combinación de al menos un inhibidor de MTP seleccionado ( componente A ) y un inhibidor de HMg - Coa reductasa ( componente B ) para la lucha contra enfermedades del sistema cardiocirculatorio, a medicamentos que contienen esta combinación y a su obtención.The invention relates to the use of a combination of at least one selected MTP inhibitor (component A) and an HMg-Coa reductase inhibitor (component B) for the fight against diseases of the cardiovascular system, drugs containing this combination and their obtaining.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19929065A DE19929065A1 (en) | 1999-06-25 | 1999-06-25 | Synergistic drug combination, especially for treating cardiovascular diseases associated with metabolic disorders, comprising bi- or tricyclic aza-heterocyclic MTP inhibitor and HMG-CoA reductase inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
UY26218A1 true UY26218A1 (en) | 2001-01-31 |
Family
ID=7912459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY26218A UY26218A1 (en) | 1999-06-25 | 2000-06-23 | COMBINATION OF MTP INHIBITORS AND HMG-COA REDUCTASE INHIBITORS AND THEIR USE IN MEDICINES. LAW 17,164.- |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP1196194A2 (en) |
JP (1) | JP2003503342A (en) |
AR (1) | AR028996A1 (en) |
AU (1) | AU5680900A (en) |
CA (1) | CA2376881A1 (en) |
DE (1) | DE19929065A1 (en) |
DO (1) | DOP2000000022A (en) |
GT (1) | GT200000099A (en) |
PE (1) | PE20010302A1 (en) |
SV (1) | SV2004000109A (en) |
UY (1) | UY26218A1 (en) |
WO (1) | WO2001000183A2 (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10030375A1 (en) * | 2000-06-21 | 2002-01-03 | Bayer Ag | Use of MTP inhibitors to lower ppTRL |
KR20060053023A (en) * | 2002-02-28 | 2006-05-19 | 니뽄 다바코 산교 가부시키가이샤 | Ester compound and medicinal use thereof |
JP4832897B2 (en) | 2003-08-29 | 2011-12-07 | 日本たばこ産業株式会社 | Ester derivatives and their pharmaceutical uses |
US8101774B2 (en) | 2004-10-18 | 2012-01-24 | Japan Tobacco Inc. | Ester derivatives and medicinal use thereof |
FR2884831B1 (en) * | 2005-04-22 | 2007-08-10 | Merck Sante Soc Par Actions Si | METHOD FOR SCREENING MTP INHIBITORY COMPOUNDS |
DE102011007272A1 (en) | 2011-04-13 | 2012-10-18 | Bayer Pharma Aktiengesellschaft | Branched 3-phenylpropionic acid derivatives and their use |
US10905667B2 (en) | 2018-07-24 | 2021-02-02 | Bayer Pharma Aktiengesellschaft | Orally administrable modified-release pharmaceutical dosage form |
CN109053927A (en) * | 2018-08-08 | 2018-12-21 | 中山大学 | A kind of amphipathic sodium alginate derivative of the group containing vitamin B12 and its preparation method and application |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE4435477A1 (en) * | 1994-10-04 | 1996-04-11 | Bayer Ag | Cycloalkano-indole and -azaindole derivatives |
DE19546918A1 (en) * | 1995-12-15 | 1997-06-19 | Bayer Ag | Bicyclic heterocycles |
DE19546919A1 (en) * | 1995-12-15 | 1997-06-19 | Bayer Ag | N-heterocyclically substituted phenylacetic acid derivatives |
DE19615265A1 (en) * | 1996-04-18 | 1997-12-04 | Bayer Ag | New pyridazino, pyrimido, pyrazino and triazinoindoles |
SK65499A3 (en) * | 1996-11-27 | 2001-05-10 | Pfizer | Apo b-secretion/mtp inhibitory amides |
CA2286341A1 (en) * | 1997-05-01 | 1998-11-12 | John R. Ii Wetterau | Mtp inhibitors and fat soluble vitamin therapeutic combinations to lower serum lipid levels |
-
1999
- 1999-06-25 DE DE19929065A patent/DE19929065A1/en not_active Withdrawn
-
2000
- 2000-06-13 WO PCT/EP2000/005410 patent/WO2001000183A2/en not_active Application Discontinuation
- 2000-06-13 EP EP00942056A patent/EP1196194A2/en not_active Withdrawn
- 2000-06-13 CA CA002376881A patent/CA2376881A1/en not_active Abandoned
- 2000-06-13 AU AU56809/00A patent/AU5680900A/en not_active Abandoned
- 2000-06-13 JP JP2001505893A patent/JP2003503342A/en active Pending
- 2000-06-21 GT GT200000099A patent/GT200000099A/en unknown
- 2000-06-22 AR ARP000103129A patent/AR028996A1/en unknown
- 2000-06-23 UY UY26218A patent/UY26218A1/en not_active Application Discontinuation
- 2000-06-23 PE PE2000000625A patent/PE20010302A1/en not_active Application Discontinuation
- 2000-06-23 SV SV2000000109A patent/SV2004000109A/en unknown
-
2008
- 2008-04-11 DO DO2000000022A patent/DOP2000000022A/en unknown
Also Published As
Publication number | Publication date |
---|---|
DE19929065A1 (en) | 2000-12-28 |
JP2003503342A (en) | 2003-01-28 |
DOP2000000022A (en) | 2008-08-15 |
PE20010302A1 (en) | 2001-04-12 |
GT200000099A (en) | 2001-12-13 |
AU5680900A (en) | 2001-01-31 |
AR028996A1 (en) | 2003-06-04 |
WO2001000183A2 (en) | 2001-01-04 |
SV2004000109A (en) | 2004-05-07 |
CA2376881A1 (en) | 2001-01-04 |
EP1196194A2 (en) | 2002-04-17 |
WO2001000183A3 (en) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DOP2000000022A (en) | COMBINATION OF MTP INHIBITORS AND INHIBITORS OF HMG-COA REDUCTASA AND ITS USE IN MEDICINES. | |
DOP2019000185A (en) | A SOLID PHARMACEUTICAL DOSAGE FORMULATION | |
BRPI0413363A (en) | dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors | |
PA8523901A1 (en) | PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE ESTER CHOLESTERILE TRANSFER PROTEIN | |
CY1120313T1 (en) | MEDICINAL COMPOSITION FOR LEATHER USE TO TREAT PREVENTION WHICH INCLUDES Vitamin D And Corticosteroids | |
PA8564901A1 (en) | PHARMACEUTICAL COMPOSITIONS OF INHIBITORS OF THE CHOLESTERILE ESTERES TRANSFER PROTEIN | |
BR0317715A (en) | Compositions and processes of use of collajolie | |
PA8513601A1 (en) | PHARMACEUTICAL COMPOSITIONS OF GLUCOGENOPHOSPHORILASE INHIBITORS | |
BR0012046A (en) | Heterocyclic compound, pharmaceutical composition, inhibitor of activation of ap-1 or an inhibitor of activation of nf-kappab, inhibitor of the production of inflammatory cytokine, and inhibitor of the production of matrix metalloprotease or inhibitor of the expression of inflammatory cell adhesion factor | |
EE04990B1 (en) | Pharmaceutical compositions containing an HMG reductase inhibitor, their use and method of preparation | |
CY1107294T1 (en) | LOCAL COMPOSITION CONTAINING A VITAMIN D OR A VERSION OF VITAMIN D AND A VULNERABLE CYTICOSTEROID | |
ES2188177T3 (en) | COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF OSTEOPOROSIS AND ALTERATIONS DUE TO MENOPAUSE SYNDROME, WHICH INCLUDES PROPIONIL-L-CARNITINE AND GENISTEINE. | |
PA8577901A1 (en) | PHARMACEUTICAL FORMULATION | |
BRPI0507654A (en) | pharmaceutical composition comprising a benzodiazepine derivative and an rsv fusion protein inhibitor | |
WO2007053641A3 (en) | A-type procyanidins and inflammation | |
TW200510002A (en) | Solid pharmaceutical preparation | |
CL2004000366A1 (en) | USE OF A COMBINATION OF A QUINASA P38 INHIBITING DERIVED COMPOUND OF PIRAZOL, AND AN ACE INHIBITOR TO TREAT RENAL DYSFUNCTION, CARDIOVASCULAR AND VASCULAR DISEASE, RETINOPATHY, NEUROPATIA, EDOTEL, INSOTUNATIO OPINION. | |
PT991654E (en) | NEW DERIVATIVES OF 2- (IMINOMETHYL) AMINO-PHENYL ITS PREPARATION ITS APPLICATION AS MEDICATIONS AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM | |
BR0110506A (en) | Use of il-18 inhibitors for the treatment and / or prevention of atherosclerosis. | |
HUP0401854A2 (en) | Combinations comprising cox-2 inhibitors and aspirin | |
DK0991424T3 (en) | Pharmaceutical compositions comprising an aldose reductase inhibitor and an ACE inhibitor | |
UY27753A1 (en) | PHARMACEUTICAL FORMULATION THAT MELATONINE INCLUDES. | |
EA199901043A1 (en) | PHARMACEUTICAL TRANSFERASE INHIBITORS IN A COMBINATION WITH HMG-CoA REDUCTASE INHIBITORS FOR CANCER TREATMENT | |
AR021249A1 (en) | COMPOSITION OF NON-STICKY WHITE CONFITURE. | |
DE60041198D1 (en) | ANTIMICROBIAL COMPOSITIONS |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20110721 |